<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01979393</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62113-55115</org_study_id>
    <secondary_id>2013-000762-11</secondary_id>
    <secondary_id>UC1306</secondary_id>
    <nct_id>NCT01979393</nct_id>
  </id_info>
  <brief_title>IRCI Gynae Sarcomas, High Grade Uterine Sarcoma</brief_title>
  <official_title>A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs&#xD;
      that have effects on tumour growth, blood supply, invasion and spread.&#xD;
&#xD;
      Therefore, we want to find out whether taking cabozantinib after treatment with surgery and&#xD;
      chemotherapy is effective and safe for patients who responded or had stable disease after&#xD;
      their chemotherapy.&#xD;
&#xD;
      All participants will receive 4-6 cycles of standard chemotherapy. Those with stabilization&#xD;
      or response to the standard chemotherapy will be split into 2 groups (cabozantinib or&#xD;
      placebo).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3.5 years from first patient in</time_frame>
    <description>The primary endpoint is PFS rate at 4 months after randomization to cabozantinib or placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3.5 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3.5 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>3.5 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response to cabozantinib</measure>
    <time_frame>3.5 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate to anthracycline-based chemotherapy for the patients with measurable disease</measure>
    <time_frame>3.5 years from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of global health status/QoL scale</measure>
    <time_frame>3.5 years from first patient in</time_frame>
    <description>The primary health-related quality of life endpoint that is considered of interest for this study is the global health status/QoL scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of Adverse Events</measure>
    <time_frame>3.5 years from first patient in</time_frame>
    <description>This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Uterine Sarcoma</condition>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are suitable for treatment with doxorubicin +/- ifosfamide and fall&#xD;
             within one of the following patient populations:&#xD;
&#xD;
             • HGUS, HGESS, HGLMS and HG adenosarcoma&#xD;
&#xD;
               -  FIGO stage II and stage III : if adjuvant chemotherapy is proposed&#xD;
&#xD;
               -  FIGO stage IV: if first line chemotherapy is proposed&#xD;
&#xD;
          -  Metastatic: diagnosed with disease relapse after local treatment for primary tumor&#xD;
&#xD;
          -  at least 18 years old&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  Central pathological confirmation: Histological evidence of HGUS, HGESS, HGLMS and HG&#xD;
             adenosarcoma&#xD;
&#xD;
          -  Non-progressive patients (CR, PR, SD) at the end of the first line treatment (standard&#xD;
             chemotherapy consisting of 4 to 6 cycles of anthracyclines alone or in combination&#xD;
             with ifosfamide)&#xD;
&#xD;
          -  WHO/ECOG performance status 0-2&#xD;
&#xD;
          -  Adequate organ and bone marrow function within 3 days prior to the first dose of study&#xD;
             treatment (Cabozantinib/placebo)&#xD;
&#xD;
          -  Clinically normal cardiac function&#xD;
&#xD;
          -  Women of child bearing potential must have a negative serum/urine pregnancy test&#xD;
             within 3 days prior to the first dose of study treatment&#xD;
&#xD;
          -  Adequate birth control measures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  low-grade ESS, leiomyosarcoma (low or intermediate), carcinosarcoma, low-grade&#xD;
             adenosarcoma, rhabdomyosarcoma (alveolar or embryonal) and soft tissue PNET of&#xD;
             uterus/cervix.&#xD;
&#xD;
          -  contraindications to cabozantinib&#xD;
&#xD;
          -  not able to swallow and retain oral tablets&#xD;
&#xD;
          -  planned use of chemotherapy, radiation therapy, radionuclide treatment, small molecule&#xD;
             tyrosine kinase inhibitor or hormonal therapy, and any other investigational agent&#xD;
             (Cabozantinib/placebo) during the treatment period&#xD;
&#xD;
          -  concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before&#xD;
             the first dose of study treatment&#xD;
&#xD;
          -  patient with poorly controlled hypertension defined at baseline as blood pressure&#xD;
             &gt;150/90&#xD;
&#xD;
          -  patients who have suffered a cerebrovascular accident at any time in the past,&#xD;
             patients who have suffered a transient ischemic attack in the past 6 months, patients&#xD;
             who have suffered a deep venous thrombosis (DVT) or a pulmonary embolism in the past 6&#xD;
             months&#xD;
&#xD;
          -  Gastrointestinal disorders&#xD;
&#xD;
          -  patients with radiographic evidence of cavitating pulmonary lesion(s)&#xD;
&#xD;
          -  patients with tumor in contact with, invading or encasing any major blood vessels&#xD;
&#xD;
          -  patients evidence of tumor invading the GI tract&#xD;
&#xD;
          -  evidence of active bleeding or bleeding diathesis&#xD;
&#xD;
          -  hemoptysis ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose&#xD;
             of study treatment&#xD;
&#xD;
          -  signs indicative of pulmonary hemorrhage within 3 months before the first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  clinically-significant gastrointestinal bleeding within 6 months before the first dose&#xD;
             of study treatment&#xD;
&#xD;
          -  prior major surgery or trauma within 6 weeks prior to first dose of study drug and any&#xD;
             wound, fracture, or ulcer should be completely healed&#xD;
&#xD;
          -  concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450&#xD;
             3A4/5&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Ray-Coquard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Léon Bérard, Lyon, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Reed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital , Glasgow, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois-Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital NHS - Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced</keyword>
  <keyword>stage III</keyword>
  <keyword>stage IV</keyword>
  <keyword>residual disease after primary surgery</keyword>
  <keyword>newly diagnosed HGUS</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

